Target intelligence / Profile preview

Transcriptional adapter 2-alpha (TADA2A)

Target
TADA2A
Molecular classification
Other (transcriptional coactivator), Histone modification (adaptor in histone acetylation complexes, e.g., PCAF and ATAC)
01

Overview

Transcriptional adapter 2-alpha (TADA2A) is a nuclear protein that acts as a transcriptional coactivator, functioning as an adaptor to bridge sequence-specific DNA-binding transcription factors with the general transcription machinery of RNA polymerase II. It serves as an integral component of large multi-subunit histone acetyltransferase complexes, notably the PCAF and ATAC complexes, which acetylate histones H3 and H4 and facilitate chromatin remodeling and transcriptional activation. TADA2A is essential for modulating chromatin accessibility, promoting gene expression through nucleosome acetylation, and is involved in several critical cellular processes, including cell cycle progression, DNA repair, and apoptosis through its regulatory interactions. The gene is subject to alternative splicing and has several transcript variants, and while not itself a direct therapeutic drug target, its dysregulation is associated with cancer, with circTADA2A—a circular RNA derived from TADA2A—emerging as a potential biomarker for certain malignancies

Other names
Transcriptional adapter 2ATADA2ATADA2LKL04PADA2-like proteinADA2hADA2ADA2ATranscriptional adapter 2-likeTranscriptional adapter 2-alpha
02

Mechanism of action

Not applicable/none established (as above, no direct targeting drugs; function is as a regulatory subunit in chromatin-modifying complexes)

03

Biological functions

Transcriptional coactivation (bridges DNA-binding transcription factors and general transcription machinery)Chromatin remodeling (participates in nucleosome acetylation and destabilization to facilitate gene activation)Histone acetylation adaptor (part of complexes like PCAF and ATAC targeting histones H3 and H4)DNA binding (double-stranded DNA, dinucleosome binding)
04

Disease associations

Cancer (dysregulation implicated in several malignancies such as breast cancer, colorectal cancer, osteosarcoma, and non-small cell lung cancer, mainly through its circular RNA—circTADA2A)Chromosome 17q12 deletion syndromeRenal cysts and diabetes syndromeOther roles suggested by involvement in chromatin structure and gene expression regulation, but specific direct pathogenic roles are usually attributed to indirect effects
05

Biomarkers

circular RNA derived from TADA2A (circTADA2A) has been proposed as a diagnostic/prognostic biomarker in several cancers, including non-small cell lung cancer and triple-negative breast cancer, due to its dysregulated expression

Beyond the preview

Go deeper on Transcriptional adapter 2-alpha (TADA2A).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Transcriptional adapter 2-alpha (TADA2A).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call